Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury.

However, SS-31 treatment significantly improved BMS scores from 1 week up to 6 weeks post-injury in a dose-dependent manner, although the improvement in the 5 mg SS-31 group did not reach statistical significance ( Figure 4 A).

also in 111,027 other papers